| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
In this study, I examined the therapeutic performance of hemoglobin-based carbon monoxide (CO) donor, CO-bound hemoglobin-vesicles and CO-bound red blood cells, against disaster-related disorders with focus on acute kidney injury (AKI) induced by crush syndrome. A single administration of CO donors was found to effectively suppress the pathogenesis of AKI with the mortality in crush syndrome model rats being improved. In addition, CO donors were found to have renoprotective effects via the suppression of subsequent heme protein (myoglobin and cytochrome P450)-associated renal oxidative injury. These findings suggest that these CO donors have the potential for use as a novel therapy against crush syndrome-induced AKI.
|
